Truist Financial Boosts Fresenius Medical Care (NYSE:FMS) Price Target to $25.00

Fresenius Medical Care (NYSE:FMS - Get Free Report) had its price target lifted by stock analysts at Truist Financial from $23.00 to $25.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a "hold" rating on the stock. Truist Financial's price objective would indicate a potential upside of 9.70% from the stock's previous close.

A number of other brokerages have also recently commented on FMS. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Friday. They issued a "strong-buy" rating for the company. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th. They issued a "buy" rating and a $25.60 price objective for the company. Finally, Bank of America upgraded Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $25.30.

Fresenius Medical Care Price Performance

NYSE FMS traded up $0.41 during mid-day trading on Monday, hitting $22.79. The stock had a trading volume of 199,147 shares, compared to its average volume of 206,582. The firm's 50 day moving average is $22.24 and its 200 day moving average is $20.67. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The stock has a market capitalization of $13.37 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 0.95 and a beta of 0.94. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $24.31.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers grew its stake in shares of Fresenius Medical Care by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 18,067 shares of the company's stock valued at $345,000 after buying an additional 1,128 shares during the period. Caprock Group LLC purchased a new position in Fresenius Medical Care in the second quarter worth approximately $208,000. Koss Olinger Consulting LLC acquired a new stake in Fresenius Medical Care during the second quarter worth $286,000. American Century Companies Inc. raised its position in Fresenius Medical Care by 29.3% in the second quarter. American Century Companies Inc. now owns 24,046 shares of the company's stock valued at $459,000 after purchasing an additional 5,445 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Fresenius Medical Care by 14.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 12,539 shares of the company's stock valued at $239,000 after purchasing an additional 1,576 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.